32 Advanced Solid Tumors Clinical Trials in Philadelphia, PA (2026)

Q: How do I join a clinical trial in Philadelphia?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you.

Recruiting Advanced Solid Tumors Studies in Philadelphia

NCT06179160Recruiting

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation

This study is conducted to determine the safety and tolerability of INCB161734 as a single agent or in combination with other anticancer therapies....

Philadelphia, PAPHASE1710 participantsIncyte Corporation

View Study Details

NCT05836324Recruiting

A Study to Evaluate the Safety of INCA33890 in Participants With Advanced or Metastatic Solid Tumors

To evaluate the safety, tolerability, and DLTs and determine the MTD and/or RDE(s) of INCA33890 in participants with select advanced or metastatic solid tumors....

Philadelphia, PAPHASE1570 participantsIncyte Corporation

View Study Details

NCT06589596Recruiting

An Investigational Study of BGB-58067 As a Single Agent and in Combination With Anticancer Agents in Participants With Advanced Solid Tumors

This is an open-label, multicenter, first-in-human dose escalation and dose expansion study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity...

Philadelphia, PAPHASE1525 participantsBeOne Medicines

View Study Details

NCT07094113Recruiting

AMG 410 Alone and in Combination With Other Agents in Participants With KRAS Altered Advanced or Metastatic Solid Tumors

The purpose of this first-in-human study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary efficacy of AMG 410 when administered alone or in combin...

Philadelphia, PAPHASE1434 participantsAmgen

View Study Details

NCT06619587Recruiting

A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors

This is a first-in-human Phase I/II, open-label, multicenter, dose-escalation and expansion study designed to evaluate the safety, pharmacokinetics, and preliminary activity of GDC-7035 as a single ag...

Philadelphia, PAPHASE1410 participantsGenentech, Inc.

View Study Details

NCT06220864Recruiting

SNV1521 in Participants With Advanced Solid Tumors

This study is testing a new medicine, SNV1521, for people with advanced cancers. The researchers want to find out if SNV1521 is safe, well-tolerated, and effective in treating solid tumors. They are i...

Philadelphia, PAPHASE1400 participantsSynnovation Therapeutics, Inc.

View Study Details

NCT03686124Recruiting

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors

The study's purpose is to establish the safety and tolerability of IMA203/IMA203CD8 products with or without combination with nivolumab in patients with solid tumors that express preferentially expres...

Philadelphia, PAPHASE1375 participantsImmatics US, Inc.

View Study Details

NCT06554795Recruiting

First-in-human Study of DB-1419 for Advanced/Metastatic Solid Tumors

A Phase 1/2a First-in-Human Study of DB-1419 in Advanced/Metastatic Solid Tumors...

Philadelphia, PAPHASE1360 participantsDualityBio Inc.

View Study Details

NCT05557045Recruiting

A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815

This phase 1 study will investigate the safety, dosing, and initial antitumor activity of JZP815 in participants with advanced or metastatic solid tumors harboring alterations in the MAPK pathway....

Philadelphia, PAPHASE1332 participantsJazz Pharmaceuticals

View Study Details

NCT06736704Recruiting

SNV4818 in Participants With Advanced Solid Tumors

This study is testing a new medicine, SNV4818, for people with advanced cancers. The researchers want to find out if SNV4818 is safe, well-tolerated, and effective in treating solid tumors. They are i...

Philadelphia, PAPHASE1320 participantsPikavation Therapeutics, Inc.

View Study Details

NCT05101070Recruiting

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011. The primar...

Philadelphia, PAPHASE1282 participantsShionogi

View Study Details

NCT04777994Recruiting

Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors

The study will assess the safety, PK, PD, and preliminary efficacy of ABBV-CLS-484 as monotherapy and in combination with a PD-1 targeting agent or with a or a vascular endothelial growth factor recep...

Philadelphia, PAPHASE1248 participantsCalico Life Sciences LLC

View Study Details

NCT07205718Recruiting

A Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors

TAK-188 is a new medicine that targets a protein called CCR8, which is found on the surface of certain cells (Tregs) inside tumors. These cells can weaken the body's ability to fight cancer. TAK-188 m...

Philadelphia, PAPHASE1223 participantsTakeda

View Study Details

NCT06545942Recruiting

Study of Orally Administered MOMA-313 in Participants With Advanced or Metastatic Solid Tumors

This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clini...

Philadelphia, PAPHASE1220 participantsMOMA Therapeutics

View Study Details

NCT06795412Recruiting

Study of PYX-201 in Combination With Pembrolizumab in Advanced Solid Tumors

The primary objective of this study is to determine the recommended Phase 2 doses (RP2D(s)) and maximum tolerated dose (MTD) of PYX-201 in combination with pembrolizumab for participants with advanced...

Philadelphia, PAPHASE1220 participantsPyxis Oncology, Inc

View Study Details

NCT05907980Recruiting

A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors

This is a Phase Ia/Ib open-label, dose-escalation study to evaluate the safety and pharmacokinetics of ROSE12 as a single agent and in combination with other anti-tumor agents in patients with locally...

Philadelphia, PAPHASE1209 participantsChugai Pharmaceutical

View Study Details

NCT05422911Recruiting

Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.

The investigators have used national VHA data to demonstrate real-world efficacy of abiraterone and enzalutamide in Veterans with mCRPC. In the real-world that is the VHA, the investigators have succe...

Philadelphia, PAPHASE2192 participantsSun Pharmaceutical Industries Limited

View Study Details

NCT06108050Recruiting

JZP898 Intravenous Infusion as Monotherapy and Combination With Pembrolizumab in Adults With Advanced/Metastatic Solid Tumors

This Phase 1 first-in-human study will investigate the safety, tolerability, pharmacokinetics (PK), immunogenicity, and preliminary antitumor activity of JZP898 monotherapy as well as JZP898 in combin...

Philadelphia, PAPHASE1177 participantsJazz Pharmaceuticals

View Study Details

NCT04752826Recruiting

BI-1808 As a Single Agent and with Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20)

The goal of this first in human clinical trial is to test BI-1808 administered as single agent and in combination with pembrolizumab in subjects with advanced malignancies whose disease has progressed...

Philadelphia, PAPHASE1176 participantsBioInvent International AB

View Study Details

NCT06885281Recruiting

A Study of ZL-1310 in Participants With Selected Solid Tumors

A Phase Ib/II, Open-label, Multi-center Study of ZL-1310 in Participants With Selected Solid Tumors...

Philadelphia, PAPHASE1166 participantsZai Lab (Shanghai) Co., Ltd.

View Study Details

NCT07030257Recruiting

Study of CP-383 in Patients With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if an investigational drug CP-383 works to treat advanced cancer. It will also learn about the safety of CP-383. The main questions if aims to answer are: ...

Philadelphia, PAPHASE1150 participantsTasca Therapeutics

View Study Details

NCT06395519Recruiting

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor acti...

Philadelphia, PAPHASE1120 participants858 Therapeutics, Inc.

View Study Details

NCT07213817Recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours

This study aims to find the right dosage and evaluate the safety and effectiveness of the drug IPN60300 in adults with advanced solid tumours, which are cancers that have spread to other parts of the ...

Philadelphia, PAPHASE1114 participantsIpsen

View Study Details

NCT06014502Recruiting

Study to Evaluate IMGS-001 Treatment in Patients With Relapsed or Refractory Advanced Solid Tumors

The purpose of this Phase 1a/1b clinical trial is to test the safety of an investigational drug called IMGS-001 and to determine how well it can work in treating patients with advanced solid tumors th...

Philadelphia, PAPHASE1105 participantsImmunoGenesis

View Study Details

NCT06803680Recruiting

A Study of BGB-B455 in Adults With Advanced or Metastatic Solid Tumors

The goal of this clinical trial is to learn if BGB-B455 can treat advanced or metastatic solid tumors expressing claudin 6 (CLDN6), a protein that is found on some tumors. The main questions it aims ...

Philadelphia, PAPHASE190 participantsBeOne Medicines

View Study Details

NCT06352359Recruiting

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

This is a Phase I/II open label study of intravenous (IV) infusion of ONC-841 as a single agent or in combination in patients with advanced/metastatic solid tumors. The study will evaluate seven dose ...

Philadelphia, PAPHASE172 participantsOncoC4, Inc.

View Study Details

NCT07108114Recruiting

SLV-324 Treatment of Metastatic Solid Tumors

This is a Phase 1 dose-escalation study evaluating the safety, pharmacokinetics, pharmacodynamics, immunogenicity, and efficacy of SLV-324 across a range of dose levels when administered to subjects w...

Philadelphia, PAPHASE170 participantsSolve Therapeutics

View Study Details

NCT05329103Recruiting

A Study to Evaluate PEEL-224 in Patients With Advanced Solid Tumors

This is a first-in-human, dose escalation, repeat-dose, multi-center, open-label study evaluating safety, tolerability, PK, and preliminary antitumor activity of PEEL-224 in patients with advanced sol...

Philadelphia, PAPHASE165 participantsPeel Therapeutics Inc

View Study Details

NCT06721689Recruiting

PEEL-224, Vincristine and Temozolomide in Pediatric Solid Tumors

The phase 1 primary objective is to determine the pediatric recommended phase 2 dose (RP2D) of PEEL-224 as a single agent (phase 1A) and in combination with vincristine and temozolomide (phase 1B). Th...

Philadelphia, PAPHASE159 participantsTheodore Laetsch

View Study Details

NCT06959706Recruiting

Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TGW101 in Participants With Advanced Solid Tumors

The primary objectives of this study are to evaluate the safety and tolerability of TGW101 and determine the recommended dosing regimen(s) for further study. The secondary objectives are to assess pha...

Philadelphia, PAPHASE150 participantsTagworks Pharmaceuticals BV

View Study Details

NCT06402201Recruiting

First in Human Study of CDR404 in HLA-A*02:01 Participants With MAGE-A4 Expressing Solid Tumors

CDR404 is a highly potent and specific T-cell engaging bispecific and bivalent antibody designed for the treatment of cancers positive for the tumor-associated antigen melanoma-associated antigen 4 (M...

Philadelphia, PAPHASE142 participantsCDR-Life AG

View Study Details

NCT07192432Recruiting

Gene Therapy for HER-Positive Cancer (SENTRY-HER2)

This is a Phase 1/2, first-in-human, open-label, dose-escalating and expansion trial designed to assess the safety and efficacy of VNX-202 in patients with HER2 positive cancers....

Philadelphia, PAPHASE127 participantsVironexis Biotherapeutics Inc.

View Study Details

About Advanced Solid Tumors Clinical Trials in Philadelphia

Advanced solid tumors refer to cancers that have grown beyond the original site or spread to distant organs. Many clinical trials enroll patients with various types of advanced solid tumors to test novel therapies. These trials often investigate immunotherapy, targeted therapy, and combination approaches.

There are currently 32 advanced solid tumors clinical trials recruiting participants in Philadelphia, PA. These studies are seeking a combined 7,513 participants. Research is being sponsored by Incyte Corporation, BeOne Medicines, Amgen and 26 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Advanced Solid Tumors Clinical Trials in Philadelphia — FAQ

Are there advanced solid tumors clinical trials in Philadelphia?

Yes, there are 32 advanced solid tumors clinical trials currently recruiting in Philadelphia, PA. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Philadelphia?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Philadelphia research site will contact you about next steps.

Are clinical trials in Philadelphia free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Philadelphia studies also compensate for your time and travel.

What advanced solid tumors treatments are being tested?

The 32 active trials in Philadelphia are testing new therapies including novel drugs, biologics, and treatment approaches for advanced solid tumors.

Data updated September 7, 2026 from ClinicalTrials.gov